These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16477055)

  • 21. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 22. [Kawasaki disease in infants younger than six month of age: report of four cases].
    Zhao W; Li F; Chen LJ; Dai K
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 May; 11(5):401-3. PubMed ID: 19470268
    [No Abstract]   [Full Text] [Related]  

  • 23. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins].
    Pavese P; Brion JP; Meusnier T; Stahl JP
    Ann Med Interne (Paris); 1997; 148(3):287-8. PubMed ID: 9255342
    [No Abstract]   [Full Text] [Related]  

  • 24. Kawasaki disease: a ride for little girls too!
    Schnautz LS; Leggett P
    Crit Care Nurs Clin North Am; 2008 Sep; 20(3):265-71. PubMed ID: 18644508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG reactivation: a useful diagnostic tool even for incomplete Kawasaki disease.
    Sinha R; Balakumar T
    Arch Dis Child; 2005 Sep; 90(9):891. PubMed ID: 16113127
    [No Abstract]   [Full Text] [Related]  

  • 26. Infliximab administration effective in the treatment of refractory Kawasaki disease.
    Accomando S; Liotta A; Maggio MC; Cardella F; Corsello G
    Pediatr Allergy Immunol; 2010 Nov; 21(7):1091-2. PubMed ID: 20977502
    [No Abstract]   [Full Text] [Related]  

  • 27. Bacillus Calmette-Guérin reactivation as a sign of incomplete Kawasaki disease.
    Novais C; Fortunato F; Bicho A; Preto L
    BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 27033285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parotitis and kawasaki disease in a child with Noonan syndrome.
    Douvoyiannis M; Belamarich PF; Litman N
    Pediatr Infect Dis J; 2008 Jan; 27(1):89-90. PubMed ID: 18162955
    [No Abstract]   [Full Text] [Related]  

  • 29. Severe cutaneous manifestations in a child with refractory Kawasaki disease.
    Falcini F; Ricci L; Poggi GM; Simonini G; Calabri GB; de Martino M
    Rheumatology (Oxford); 2006 Nov; 45(11):1444-5. PubMed ID: 16847007
    [No Abstract]   [Full Text] [Related]  

  • 30. Kawasaki disease characterized by erythema and induration at the Bacillus Calmette-Guérin and purified protein derivative inoculation sites.
    Hsu YH; Wang YH; Hsu WY; Lee YP
    Pediatr Infect Dis J; 1987 Jun; 6(6):576-8. PubMed ID: 3615073
    [No Abstract]   [Full Text] [Related]  

  • 31. Kawasaki disease.
    Narayanan SN; Krishnaveni ; Sabarinathan K
    Indian Pediatr; 1997 Feb; 34(2):139-43. PubMed ID: 9255010
    [No Abstract]   [Full Text] [Related]  

  • 32. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease.
    Kuniyuki S; Asada M
    J Am Acad Dermatol; 1997 Aug; 37(2 Pt 2):303-4. PubMed ID: 9270532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bacillus Calmette-Guérin Scar Erythema: "Haloing" the Diagnosis in Kawasaki Disease.
    Gorman KM; Gavin PJ; Capra L
    J Pediatr; 2015 Sep; 167(3):774. PubMed ID: 26205182
    [No Abstract]   [Full Text] [Related]  

  • 34. Lessons from Kawasaki disease: all brands of IVIG are not equal.
    Stiehm ER
    J Pediatr; 2006 Jan; 148(1):6-8. PubMed ID: 16423589
    [No Abstract]   [Full Text] [Related]  

  • 35. [BCG reactivation: a rare but specific sign of Kawasaki disease].
    Plantin P; Blayo M; Dupré D; Schoenlaub P
    Presse Med; 1998 Apr; 27(15):716. PubMed ID: 9767910
    [No Abstract]   [Full Text] [Related]  

  • 36. [Reactivation of the scar of BCG vaccination in Kawasaki's disease: clinical case and literature review].
    García Pavón S; Staines Boone T; Hernández Bautista V; Yamazaki Nakashimada MA
    Rev Alerg Mex; 2006; 53(2):76-8. PubMed ID: 16884033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient characteristics and intravenous immunoglobulin product may affect eosinophils in Kawasaki disease.
    Kuo HC; Wang CL; Wang L; Yu HR; Yang KD
    Pediatr Allergy Immunol; 2008 Mar; 19(2):184-5. PubMed ID: 18257906
    [No Abstract]   [Full Text] [Related]  

  • 38. [Immunoglobulin in suspected Kawasaki disease].
    García Soblechero E; Gómez Santos E; Domínguez Quintero ML; González Vila L
    An Pediatr (Barc); 2010 Sep; 73(3):151-2. PubMed ID: 20605119
    [No Abstract]   [Full Text] [Related]  

  • 39. BCG and Kawasaki disease in Mexico and Japan.
    Gamez-Gonzalez LB; Hamada H; Llamas-Guillen BA; Ruiz-Fernandez M; Yamazaki-Nakashimada M
    Hum Vaccin Immunother; 2017 May; 13(5):1091-1093. PubMed ID: 28281896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Updates on diagnosis and management of Kawasaki disease unresponsive to intravenous gamma globulin].
    Wang YQ; Cao XJ
    Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):226-8. PubMed ID: 15833210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.